The goal of this research is to test the accuracy of PET/MRI imaging with 18F-fluorofuranylnorprogesterone (FFNP) for measuring progesterone receptor (PR) expression in patients with invasive breast cancer. We hypothesize that FFNP SUVmax from PET/MRI will correlate well against the semi-quantitative PR immunohistochemistry score.